The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Damayanti Kerai - Hsbc International - Analyst
: Hello. Am I audible?
Question: Damayanti Kerai - Hsbc International - Analyst
: Okay. Thank you for the opportunity. My first question is, when you look at -- when we look at your performance year-on-year for biosimilars
Question: Damayanti Kerai - Hsbc International - Analyst
: Shreehas, Thank you for that. I understand at the EBITDA level, but I was trying to understand more at the gross level performance. Thank you.
Question: Damayanti Kerai - Hsbc International - Analyst
: Sure. So I just have another question on interest expense. So before that, if you can say like what is the debt level at the parent as well as the Biocon
Biologics Limited level, and we have been talking about debt reduction for a couple of quarters, but when we look at the interest expense for the
quarter, I think it has gone up. Can you explain that as well?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 08, 2025 / 3:30AM, BION.NS - Q1 2026 Biocon Ltd Earnings Call
Question: Damayanti Kerai - Hsbc International - Analyst
: Okay. So with some of these repayments under way, should we assume interest burden to go down from 2Q itself? Or it will happen in a more
gradual manner?
Question: Damayanti Kerai - Hsbc International - Analyst
: Okay. So just like this [$1.1 billion] net debt, that is at the parent level. Sorry, I missed the --
Question: Damayanti Kerai - Hsbc International - Analyst
: And the parents?
Question: Damayanti Kerai - Hsbc International - Analyst
: Okay, 100 million. Okay. Got it. Got it. And my last question is biosimilar --
Question: Damayanti Kerai - Hsbc International - Analyst
: Sure. Sure, ma'am. I'll do that. My last question is for biosimilars, can you give us the regional split, say, like US and other markets?
Question: Damayanti Kerai - Hsbc International - Analyst
: Okay. Okay, Kedar. Thank you. I'll get back in the queue.
|